证券代码：688247 证券简称：宣泰医药 公告编号：2025-031 上海宣泰医药科技股份有限公司 关于控股股东自愿承诺不减持公司股份的公告 公司董事会将对上述承诺事项的履行情况进行持续监督并及时履行信息披 露义务。 特此公告。 上海宣泰医药科技股份有限公司董事会 2025 年 8 月 18 日 上海宣泰医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日收到公司控股股东上海联和投资有限公司（以下简称"联和投资"）出具的《关 于自愿承诺未来 24 个月不减持上海宣泰医药科技股份有限公司股份的承诺函》。 现将相关情况公告如下： 基于对公司未来发展前景的信心和对公司长期价值的认可，同时为增强广大 投资者信心，切实维护投资者权益和资本市场稳定，公司控股股东联和投资自愿 承诺，自 2025 年 8 月 25 日起 24 个月内（2025 年 8 月 25 日至 2027 年 8 月 24 日）不通过集中竞价交易、大宗交易等方式减持其所持有的公司股份。在上述承 诺期间，如发生资本公积转增股本、派送股票红利、配股等产生新增股份，亦遵 守该不减持承诺。 截至本公告披露日，公司控股股东联和投资持股情况 ...

Core Viewpoint - The controlling shareholder of Xuantai Pharmaceutical, Shanghai Lianhe Investment Co., Ltd., has voluntarily committed not to reduce its shareholding for 24 months starting from August 25, 2025, to enhance investor confidence and maintain market stability [1][4] Group 1: Shareholder Commitment - The commitment not to reduce shareholding is based on confidence in Xuantai Pharmaceutical's future development and long-term value recognition [1] - On August 25, 2023, a total of 311 million shares of Xuantai Pharmaceutical will be unlocked, accounting for 68.61% of the total share capital, with Lianhe Investment holding 233 million shares, representing 75% of the unlocked shares [1] Group 2: Business Development and Competitive Edge - Xuantai Pharmaceutical's controlling shareholder is optimistic due to the robust development of the company's core strategic business and the broad industry prospects [2] - The company has established three major technology platforms for high-barrier products in the generic drug sector, including "insoluble drug solubilization technology platform," "controlled-release drug formulation R&D platform," and "fixed-dose combination formulation R&D platform" [2] - By the end of 2024, Xuantai Pharmaceutical is expected to have 16 approved products, including several first-generic products domestically and internationally [2] Group 3: CRO/CMO Performance - In the CRO/CMO sector, Xuantai Pharmaceutical has successfully assisted in the approval of multiple innovative drugs and has developed over 100 innovative drug formulations [3] - The company has established partnerships with several listed companies and well-known pharmaceutical enterprises, providing CMO services for eight approved new drug products [3] Group 4: Investor Relations and Dividends - Xuantai Pharmaceutical prioritizes cash dividends to reward shareholders, having distributed a total of 74.36 million yuan in cash dividends since its listing in 2022, with plans for mid-term dividends in 2024 [3] - The commitment from the controlling shareholder serves as a strong vote of confidence in the company's existing development strategy and management team [4]

Core Viewpoint - The company, Xuantai Pharmaceutical (688247), announced a commitment from its controlling shareholder, Lianhe Investment, to not reduce its shareholding through various trading methods for a period of 24 months, starting from August 25, 2025, to enhance investor confidence and maintain market stability [1] Summary by Relevant Categories Company Commitment - Lianhe Investment, the controlling shareholder, voluntarily pledged to refrain from selling its shares in the company through centralized bidding or block trading for 24 months [1] Investor Confidence - The commitment aims to bolster investor confidence and protect the rights of investors, reflecting the company's confidence in its future development prospects and long-term value [1]

Group 1 - The company announced the approval of a proposal to use part of its idle raised funds for cash management, with a limit not exceeding 80 million RMB [2] - The decision was made during the 15th meeting of the second board of directors' audit committee and the 17th board meeting held on August 8, 2025 [2] - The usage period for the funds is set for 12 months from the date of board approval, allowing for rolling use within the specified limit and timeframe [2]

使用部分闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）首次公开 发行股票并上市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对公司 使用部分闲置募集资金（含超募资金）进行现金管理的事项进行了核查，具体情 况如下： 一、募集资金基本情况 国泰海通证券股份有限公司 关于上海宣泰医药科技股份有限公司 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开 发行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资金 总额为人民币 42,483.58 万元，扣除与发行相关的费用（不含增值税）人民币 4,761.77 万元，实际募集资金净额为人民币 37,721.81 万元。 上述资金到位情况经上会会计师事务所（特殊普通 ...

上海宣泰医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 8 日 召开第二届董事会审计委员会第十五次会议、第二届董事会第十七次会议审议 通过了《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在不影响 募集资金项目（以下简称"募投项目"）的建设和使用安排并有效控制风险的前 提下，合理使用额度不超过人民币 8,000 万元的部分闲置募集资金进行现金管 理。使用期限为自公司董事会审议通过之日起 12 个月内。在前述额度和期限范 围内，资金可以循环滚动使用。 公司董事会授权公司董事长在上述授权额度范围及期限内行使投资决策权 并签署相关合同等法律文件，具体事项由公司财务部负责实施。保荐机构国泰 海通证券股份有限公司（以下简称"保荐机构"）对本事项出具了明确同意的核 查意见。 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公 开发行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资 金总额为人民币 42,483.58 万元，扣除与发行相关 ...

天眼查商业履历信息显示，上海宣泰医药科技股份有限公司，成立于2012年，位于上海市，是一家以从 事研究和试验发展为主的企业。企业注册资本45334万人民币，实缴资本45334万人民币。公司法定代表 人为郭明洁。 资金流向方面，今日主力资金净流出1307.87万元，占比成交额7.27%。其中，超大单净流出1017.85万 元、占成交额5.66%，大单净流出290.02万元、占成交额1.61%，中单净流出流入414.06万元、占成交额 2.3%，小单净流入893.81万元、占成交额4.97%。 通过天眼查大数据分析，上海宣泰医药科技股份有限公司共对外投资了5家企业，参与招投标项目153 次，知识产权方面有商标信息101条，专利信息56条，此外企业还拥有行政许可36个。 来源：金融界 宣泰医药最新一期业绩显示，截至2025一季报，公司营业总收入1.09亿元、同比减少2.23%，归属净利 润2048.93万元，同比减少10.51%，扣非净利润1906.76万元，同比减少12.33%，流动比率9.733、速动比 率8.720、资产负债率11.93%。 金融界消息 截至2025年7月30日收盘，宣泰医药（688247）报 ...

Group 1 - Datang Power achieved a total on-grid electricity of approximately 123.99 billion kWh for the first half of 2025, a year-on-year increase of 1.30%, with wind and solar power generation increasing by 31.27% and 36.35% respectively [1] - North Self Technology signed an equipment procurement contract with a total amount of 164 million yuan [1] - Jinchuan Co. reported a net profit of 1.38 billion yuan for the first half of 2025, a year-on-year decrease of 8.45%, with operating revenue of 6.96 billion yuan, an increase of 5.55% [1][2] Group 2 - Microchip Biotech expects a revenue of 407 million yuan for the first half of 2025, a year-on-year increase of 35%, and a net profit of approximately 30.06 million yuan, a year-on-year increase of 173% [3] - Zongheng Co. anticipates a revenue of 135 million yuan for the first half of 2025, a year-on-year increase of 61.72%, with a net loss of 34.68 million yuan, reducing losses by 18.34 million yuan compared to the previous year [5] - Tuojing Technology expects a revenue of 1.21 billion to 1.26 billion yuan for the second quarter of 2025, a year-on-year increase of 52% to 58%, with a net profit of 238 million to 247 million yuan, a year-on-year increase of 101% to 108% [7] Group 3 - Star Power reported a net profit of 73.42 million yuan for the first half of 2025, a year-on-year decrease of 13.44%, with total revenue of 1.52 billion yuan, an increase of 13.70% [8] - Xiamen Tungsten reported a net profit of 972 million yuan for the first half of 2025, a year-on-year decrease of 4.41%, with operating revenue of 19.18 billion yuan, an increase of 11.75% [9] - Yikang Pharmaceutical's subsidiary received approval for clinical trials of YKYY029 injection for hypertension [11] Group 4 - Mould Technology received a project designation for luxury car exterior parts, with an expected total sales of 2.044 billion yuan over a five-year lifecycle [13] - Jinzhik Technology won multiple projects from the State Grid and Southern Power Grid, with a total bid amount of 133 million yuan [14] - Changjiang Media plans to use up to 700 million yuan of idle funds to purchase financial products [16] Group 5 - Ningbo Gaofa plans to invest up to 20 million USD to establish a production base in Morocco [20] - Xuantai Pharmaceutical's subsidiary received EU GMP certification for solid dosage production lines [22] - Changhua Group received a project designation for key metal structural components from a domestic new energy vehicle company, with an expected total sales of 235 million yuan over a four-year lifecycle [23]

证券代码：688247 证券简称：宣泰医药 公告编号：2025-029 上海宣泰医药科技股份有限公司 自愿披露关于全资子公司通过欧盟 GMP 认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 7 月 18 日 一、GMP 证书相关情况 二、对公司的影响及风险提示 宣泰药业本次通过欧盟 EMA 的 GMP 认证，是继其通过 NMPA（中国国家 药品监督管理局）、FDA（美国食品药品监督管理局）、PMDA（日本独立行政 法人医药品医疗器械综合机构）、SFDA（沙特阿拉伯食品药品监督管理局）等 药政当局 GMP 认证后又一次良好的认证记录，意味着公司质量体系始终保持与 企业名称：江苏宣泰药业有限公司 生产地址：南通市海门区滨江街道珠海路 163 号 证书编号：NNGYK/29521-4/2025 认证产线：固体片剂车间 签发机关：匈牙利国家公共卫生和药房中心 国际标准接轨。这将有力促进公司产品海外市场的拓展，提高公司的市场竞争力； 同时持续支持公司向全球制药企业、生物技术企业提供一站式制剂研发生产服务， ...

Core Viewpoint - Xuantai Pharmaceutical's wholly-owned subsidiary, Jiangsu Xuantai Pharmaceutical Co., Ltd., has received the EU GMP certification, enhancing its international quality standards and market competitiveness [1] Group 1: Certification Achievements - The company has obtained the GMP certificate from the Hungarian National Public Health and Pharmacy Center for its solid tablet production line [1] - This certification follows previous GMP certifications from NMPA, FDA, PMDA, and SFDA, indicating a consistent alignment with international standards [1] Group 2: Market Implications - The EU GMP certification is expected to facilitate the company's expansion into overseas markets and improve its market competitiveness [1] - However, the production and sales of pharmaceuticals may be influenced by various factors such as market environment and channel expansion, leading to uncertainties in short-term operational performance [1]